Fifteen children with mediastinal nonHodgkin's lymphoma were treated with MRC UKALL X, the current national protocol for acute lymphoblastic leukaemia. The treatment was well tolerated, and in a minimum follow up period of 46 months the event free survival of 93% was significantly better than that in a group of historical controls treated with intermittent chemotherapy regimens whose survival was only 57%. We conclude that intensive induction and consolidation treatment, with continued oral drugs, provides an effective approach to the management of mediastinal non-Hodgkin's lymphoma.
K Wheeler, J M Chessells
Abstract Fifteen children with mediastinal nonHodgkin's lymphoma were treated with MRC UKALL X, the current national protocol for acute lymphoblastic leukaemia. The treatment was well tolerated, and in a minimum follow up period of 46 months the event free survival of 93% was significantly better than that in a group of historical controls treated with intermittent chemotherapy regimens whose survival was only 57%. We conclude that intensive induction and consolidation treatment, with continued oral drugs, provides an effective approach to the management of mediastinal non-Hodgkin's lymphoma.
Mediastinal non-Hodgkin's lymphoma is an aggressive disease with a high risk of dissemination to the bone marrow and the central nervous system. Histological examination of the biopsy specimen of the mass or of the associated lymph nodes usually shows the features of lymphoblastic lymphoma, and immunological classification shows that nearly all these tumours have the features of immature T cells.' The relationship of T cell leukaemia to lymphoma is controversial, and there has been long standing debate about whether treatment should comprise an intermittent multiple drug regimen, or Eventfree survival in study patients and historical controls. The number ofchildren who have been followed up for longer than 10 years is shown in parentheses.
tion was, however, similar. During the continuation of the treatment there were eight episodes of fever and neutropenia among the children with lymphoma, and there was one case each of varicella, Pneumocystis carinii pneumonitis, and candida pneumonia.
Discussion
These results show that a satisfactory outcome can be achieved in children with mediastinal (T cell) lymphoma using a regimen similar to that recommended for acute lymphoblastic leukaemia. We confined the report to children in whom the bone marrow was not affected, because of the problems of distinguishing acute lymphoblastic leukaemia from non-Hodgkin's lymphoma in children with marrow disease. Although this distinction may be an arbitrary one, we wanted to ensure that all the cases included would be unequivocally categorised as lymphoma. Despite the intensity of induction and consolidation, the short term toxicity of treatment was acceptable; as expected there were less infective problems during induction than in children with acute lymphoblastic leukaemia, because in no child was the bone marrow affected initially. Our results were achieved without local irradiation, which was given to only one child as emergency treatment for mediastinal obstruction. It seems that if chemotherapy is sufficiently intensive, local irradiation is not necessary to achieve either remission or long term survival. Treatment to the central nervous system is essential because of the tendency of lymphoma to recur in the central nervous system, and our patients received cranial irradiation and intrathecal methotrexate. The morbidity of cranial irradiation is well described, and it remains to be established whether intrathecal and systemic chemotherapy will provide an effective and less toxic substitute.
The results of this pilot study suggest that the UKALL X protocol is an effective treatment for mediastinal non-Hodgkin's lymphoma without bone marrow involvement. The protocol has since been adopted by the UKCCSG for national use so that confirmation of its efficacy and assessment of results in patients with stage IV disease should ultimately be available. .
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